UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies [Corrigendum]

Neuropsychiatric disease and treatment, 2021-05, Vol.17, p.1481-1482

2021

Volltextzugriff (PDF)

P.3.d.053 Cariprazine as monotherapy for the treatment of schizophrenia patients with predominant negative symptoms: a double-blind, active controlled trial

European neuropsychopharmacology, 2015-09, Vol.25, p.S510-S510

2015

Volltextzugriff (PDF)

Cognitive estimation in mild Alzheimer's disease

Journal of Neural Transmission, 2007-11, Vol.114 (11), p.1479-1484

2007

Volltextzugriff (PDF)

S.08.05 Cariprazine, the new broad spectrum antipsychotic: Clinical data of schizophrenia, bipolar mania, bipolar depression and major depression studies

European neuropsychopharmacology, 2019, Vol.29, p.S11-S11

2019

Volltextzugriff (PDF)

P.0676 Efficacy of cariprazine in bipolar I disorder in light of its receptor profile

European neuropsychopharmacology, 2021-12, Vol.53, p.S495-S496

2021

Volltextzugriff (PDF)

P.387 Correlation analysis of symptomatic and functional improvements of patients with predominant negative symptom of schizophrenia

European neuropsychopharmacology, 2019-12, Vol.29, p.S274-S275

2019

Volltextzugriff (PDF)

P.0904 Results of a phase 1 trial investigating the effect of cariprazine on the pharmacokinetics of a combined oral contraceptive

European neuropsychopharmacology, 2021-12, Vol.53, p.S664-S665

2021

Volltextzugriff (PDF)

Cariprazine, a selective dopamine D3 receptor partial agonist with unique features to treat schizophrenia negative and cognitive symptoms

European neuropsychopharmacology, 2019, Vol.29, p.S398-S399

2019

Volltextzugriff (PDF)

P.456 Akathisia during cariprazine treatment: Post-hoc analyses of pooled schizophrenia studies

European neuropsychopharmacology, 2019-12, Vol.29, p.S322-S323

2019

Volltextzugriff (PDF)

P.388 Clinical improvement of patients with predominant negative symptoms of schizophrenia: Post-hoc analysis of cariprazine versus risperidone

European neuropsychopharmacology, 2019-12, Vol.29, p.S275-S275

2019

Volltextzugriff (PDF)

Safety profile of cariprazine: Post hoc analysis of safety parameters of pooled cariprazine schizophrenia studies

European neuropsychopharmacology, 2019, Vol.29, p.S419-S419

2019

Volltextzugriff (PDF)

Efficacy of cariprazine in the treatment of negative symptoms of schizophrenia: Post hoc analyses versus aripiprazole

European neuropsychopharmacology, 2019, Vol.29, p.S417-S418

2019

Volltextzugriff (PDF)

P.3.b.021 - Safety profile of cariprazine in patients with predominant negative symptoms of schizophrenia

European neuropsychopharmacology, 2017-10, Vol.27, p.S903-S903

2017

Volltextzugriff (PDF)

Safety profile of cariprazine in patients with predominant negative symptoms of schizophrenia

European neuropsychopharmacology, 2017-10, Vol.27, p.S903

2017

Volltextzugriff (PDF)

P.3.b.020 - Cariprazine vs risperidone efficacy on predominant negative symptoms of schizophrenia: post hoc analysis of negative symptoms subdomains

European neuropsychopharmacology, 2017-10, Vol.27, p.S902-S903

2017

Volltextzugriff (PDF)

Cariprazine vs risperidone efficacy on predominant negative symptoms of schizophrenia: post hoc analysis of negative symptoms subdomains

European neuropsychopharmacology, 2017-10, Vol.27, p.S902-S903

2017

Volltextzugriff (PDF)

Cariprazine’s efficacy in treating affective symptoms – pooled data from schizophrenia and bipolar depression trials

European psychiatry, 2022-06, Vol.65 (S1), p.S156-S157

2022

Volltextzugriff (PDF)

Defining the therapeutic reference range for cariprazine

European psychiatry, 2023-03, Vol.66 (S1), p.S559-S559

2023

Volltextzugriff (PDF)

Efficacy of cariprazine on predominant negative symptoms of patients with schizophrenia: post hoc analysis of PANSS data, Marder factors, and cognition

European neuropsychopharmacology, 2016-10, Vol.26, p.S550-S550

2016

Volltextzugriff (PDF)

The efficacy of cariprazine in chronic schizophrenia – post hoc analyses of phase II/III clinical trials

European psychiatry, 2022-06, Vol.65 (S1), p.S323-S323

2022

Volltextzugriff (PDF)

Benzodiazepine use during cariprazine treatment in acute schizophrenia

European psychiatry, 2022-06, Vol.65 (S1), p.S98-S98

2022

Volltextzugriff (PDF)

The Role of Partial Agonists and Specifically Cariprazine in Dual Disorders

European psychiatry, 2024-08, Vol.67 (S1), p.S215-S215

2024

Volltextzugriff (PDF)

Predominant negative symptoms: views of patients vs. doctors in a 1-year observational study

European psychiatry, 2024-08, Vol.67 (S1), p.S171-S172

2024

Volltextzugriff (PDF)

Relapse prevention with cariprazine in patients with early-stage schizophrenia

European psychiatry, 2024-08, Vol.67 (S1), p.S291-S291

2024

Volltextzugriff (PDF)

Tolerability of cariprazine in the early stage of schizophrenia: A pooled, post-hoc analysis of 4 phase ii/iii double-blind placebo-controlled trials

European psychiatry, 2021-04, Vol.64 (S1), p.S524-S525

2021

Volltextzugriff (PDF)

1 – 25 von 72

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(67)
Mit Volltextzugriff
(62)

Publikationsform

Artikel
(71)
Buchkapitel
(1)

Sprache

Englisch
(72)
Croatian
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies [Corrigendum]

P.3.d.053 Cariprazine as monotherapy for the treatment of schizophrenia patients with predominant negative symptoms: a double-blind, active controlled trial

Cognitive estimation in mild Alzheimer's disease

S.08.05 Cariprazine, the new broad spectrum antipsychotic: Clinical data of schizophrenia, bipolar mania, bipolar depression and major depression studies

P.0676 Efficacy of cariprazine in bipolar I disorder in light of its receptor profile

P.387 Correlation analysis of symptomatic and functional improvements of patients with predominant negative symptom of schizophrenia

P.0904 Results of a phase 1 trial investigating the effect of cariprazine on the pharmacokinetics of a combined oral contraceptive

Cariprazine, a selective dopamine D3 receptor partial agonist with unique features to treat schizophrenia negative and cognitive symptoms

P.456 Akathisia during cariprazine treatment: Post-hoc analyses of pooled schizophrenia studies

P.388 Clinical improvement of patients with predominant negative symptoms of schizophrenia: Post-hoc analysis of cariprazine versus risperidone

Safety profile of cariprazine: Post hoc analysis of safety parameters of pooled cariprazine schizophrenia studies

Efficacy of cariprazine in the treatment of negative symptoms of schizophrenia: Post hoc analyses versus aripiprazole

P.3.b.021 - Safety profile of cariprazine in patients with predominant negative symptoms of schizophrenia

Safety profile of cariprazine in patients with predominant negative symptoms of schizophrenia

P.3.b.020 - Cariprazine vs risperidone efficacy on predominant negative symptoms of schizophrenia: post hoc analysis of negative symptoms subdomains

Cariprazine vs risperidone efficacy on predominant negative symptoms of schizophrenia: post hoc analysis of negative symptoms subdomains

Cariprazine’s efficacy in treating affective symptoms – pooled data from schizophrenia and bipolar depression trials

Defining the therapeutic reference range for cariprazine

Efficacy of cariprazine on predominant negative symptoms of patients with schizophrenia: post hoc analysis of PANSS data, Marder factors, and cognition

The efficacy of cariprazine in chronic schizophrenia – post hoc analyses of phase II/III clinical trials

Benzodiazepine use during cariprazine treatment in acute schizophrenia

The Role of Partial Agonists and Specifically Cariprazine in Dual Disorders

Predominant negative symptoms: views of patients vs. doctors in a 1-year observational study

Relapse prevention with cariprazine in patients with early-stage schizophrenia

Tolerability of cariprazine in the early stage of schizophrenia: A pooled, post-hoc analysis of 4 phase ii/iii double-blind placebo-controlled trials

Suchergebnisse filtern